Hypertension Diagnostics, Inc.
HDII · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $4 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $3 |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | – | – | – | 25.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -4.2% |
| Other Income/Exp. Net | $0 | $0 | $4 | $0 |
| Pre-Tax Income | -$0 | -$0 | $3 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | $3 | -$0 |
| % Margin | – | – | – | -3.3% |
| EPS | -0 | -0 | 0.024 | -0.001 |
| % Growth | -300% | -100.4% | 2,777.8% | – |
| EPS Diluted | -0 | -0 | 0.024 | -0.001 |
| Weighted Avg Shares Out | 213 | 149 | 137 | 137 |
| Weighted Avg Shares Out Dil | 213 | 149 | 137 | 137 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $4 | $0 |
| % Margin | – | – | – | 1.9% |